跳至主要内容
临床试验/CTRI/2024/06/068554
CTRI/2024/06/068554尚未招募4 期

A real world assessment for Safety and effectiveness of VORtioxeTine and Escitalopram with Clonazepam in anXious depression - VORTEX STUDY

TORRENT PHARMA0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Male or female patients 18 to 65 years with DSM-V defined MDD with anxious
  • depression.
  • Treatment naïve patients or known cases already on VOR or ESC not exceeding two weeks of active treatment.
  • ? Patients with MADRS score is greater than 20 and HAM-A score is greater than 25.
  • Patient with normal physical examination clinical laboratory and ECG findings (as per
  • physicians discretion)
  • Patients who are willing to sign the informed consent form

排除标准

  • Patient aged less than 18 years and more than 65 years will be excluded.
  • Patient with MADRS less than 19 and HAM-A less than 24.
  • Patients requiring second generation antipsychotics or lithium.
  • Patient in which the use of benzodiazepine is contraindicated.
  • Patient with other conditions who do not fit into the criteria of the study as per the
  • Patient with known hypersensitivity to Vortioxetine, Escitalopram, Clonazepam or any
  • excipients.
  • Patients who are not willing to sign the informed consent form

研究者

相似试验